Transplant diagnostics company Verici Dx plc (LSE:VRCI) has launched a placing to raise about £8.0 million gross by issuing 4.0 billion new shares at 0.2p each. The bookbuild was still to close when the launch was announced, so the final outcome had not been confirmed.
What was announced
Verici Dx plc (LSE:VRCI) announced on 8 October 2026 the launch of a proposed placing and notice of a general meeting. The company is seeking about £8.0 million before fees, or about £7.4 million net, through the issue of 4,000,000,000 new ordinary shares at 0.2p per share. The price is a discount of about 11.1% to the closing mid-market price of 0.225p on 30 September 2026.
This is the launch of the placing, not its result. The placing is being run as an accelerated bookbuild for institutional investors and was expected to close by 6.00pm on 8 October 2026, with the result to follow in a separate announcement. The placing is not underwritten. Singer Capital Markets and Oberon Capital are joint Brokers and bookrunners, with Singer also acting as nominated adviser. The company said one or more directors are expected to participate, with details to come in the result announcement.
Structure and timetable
The new shares represent roughly 175% of the existing issued share capital. The placing is split into two tranches. A firm placing of about 1,683.5 million shares, raising about £3.4 million, uses existing Shareholder authorities and is expected to be admitted on 13 October 2026. A conditional placing of about 2,316.5 million shares, raising about £4.6 million, requires shareholder approval at a general meeting on 27 October 2026, with admission expected on 28 October 2026.
Alongside the placing, a retail offer of up to £250,000 at the same price will run through the Winterflood Retail Access Platform (WRAP). It is expected to open on 9 October and close on 12 October 2026. The placing is not conditional on the retail offer.
Trading in the shares has been suspended since 7.30am on 1 October 2026, when the company entered a Capital Access Window under AIM's rules. The company said the window was intended to reach a wider range of investors during market sounding. Trading is expected to resume at 7.30am on 13 October 2026.
Use of proceeds and trading background
Verici Dx said the money will fund hiring in its commercial team and further strategic appointments, Marketing to key opinion leaders and at conferences, Capital Expenditure mainly on laboratory equipment, and Working Capital to fund operations through FY2028.
The company reported Tutivia Revenue of $1.8 million in the first half of 2026, up from $1.2 million a year earlier, and said orders in the third quarter of 2026 were about 52% higher than in the same period of 2025. Cash stood at $2.4 million at 30 June 2026, down from $3.3 million at the end of 2025. The company forecasts 2026 Tutivia revenue of $4.75 million and, if that is achieved, management expects the proceeds to fund the Business to cash-flow breakeven by the end of 2027. These are the company's own forecasts. Verici Dx raised £2.6 million gross in June 2026.
Chief Executive Sara Barrington said: "H1 2026 has been a positive and progressive period for Verici Dx."
Risks and what to watch next
The company listed principal risks including the possible need for further funding, dependence on payor reimbursement and clinical Utility for its products, reliance on key staff, laboratory regulation and data security. It said commercial payor processes are slower than it had forecast.
The next steps are the result of the bookbuild, the outcome of the WRAP retail offer, the resumption of trading on 13 October and the shareholder vote on 27 October, which the conditional Tranche depends on. The size of directors' participation will also be confirmed.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...